Top

Published in:

01-10-2018 | Original Article

The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge

Published in: Heart and Vessels | Issue 10/2018

Abstract

Tolvaptan (TLV) is a newly developed oral vasopressin-2 receptor antagonist that is mostly used for patients with acute decompensated heart failure (ADHF) refractory to conventional diuretic therapy. The aim of this study was to investigate the effects of outpatient TLV dose on cardiac mortality in patients discharged after hospitalization for ADHF. One hundred and five patients with ADHF who had been treated with TLV for the first time during hospitalization were retrospectively divided into three groups based on outpatient TLV use and dose. The non-TLV group comprised patients who were not treated with TLV after discharge (n = 36). Patients who continued TLV after discharge were further classified into two groups: low-dose (LD)-TLV (3.75 mg/day, n = 27) and high-dose (HD)-TLV (7.5 or 15 mg/day, n = 42). The primary endpoint was cardiac mortality. Secondary endpoint included the composite of all-cause mortality or re-hospitalization due to worsening of ADHF. There were no significant differences in demographic variables other than body mass index (p = 0.0026), echocardiographic data, laboratory data other than serum chloride before TLV administration (p = 0.041), serum sodium (p = 0.040) and potassium (p = 0.027) at discharge, and concomitant medications among the three groups. The Kaplan–Meier curve showed that the survival rate was lower in HD-TLV than in non-TLV, whereas LD-TLV showed the highest survival rate among the three groups (p = 0.0001). Multivariable Cox regression analysis of the clinical characteristics used for predicting cardiac mortality revealed that LD-TLV (hazard ratio [HR] 0.16, 95% confidence interval [CI] 0.01–0.93, p = 0.040) and HD-TLV (HR 2.43, 95% CI 1.06–6.26, p = 0.035) were significant predictors after adjustment for predictive covariates. In conclusion, the judgement of the continuation of LD-TLV according to patient hemodynamics and severity of congestion may not cause worsened prognosis.

McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441–1446CrossRefPubMed

McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, ESC Committee for Practice Guidelines (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847CrossRefPubMed

Abdel-Qadir HM, Tu JV, Yun L, Austin PC, Newton GE, Lee DS (2010) Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J 160:264–271CrossRefPubMed

Eshaghian S, Horwich TB, Fonarow GC (2006) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97:1759–1764CrossRefPubMed

Harjai KJ, Dinshaw HK, Nunez E, Shah M, Thompson H, Turgut T, Ventura HO (1999) The prognostic implications of outpatient diuretic dose in heart failure. Int J Cardiol 71:219–225CrossRefPubMed

Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, Yao A, Komuro I (2014) Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 78:2240–2249CrossRefPubMed

Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA (2001) Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104:2417–2423CrossRefPubMed

Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297:1332–1343CrossRefPubMed

Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O’Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA (2007) Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 49:2151–2159CrossRefPubMed

10.

Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Imai R, Ozaki Y, Watanabe T, Teraoka T, Watarai M, Murohara T (2017) Safety and efficacy of long-term use of tolvaptan in patients with heart failure and chronic kidney disease. Circ J 81:1736–1738CrossRefPubMed

11.

Okabe T, Yakushiji T, Igawa W, Ono M, Kido T, Ebara S, Yamashita K, Yamamoto MH, Saito S, Hoshimoto K, Amemiya K, Isomura N, Araki H, Ochiai M (2015) The efficacy of tolvaptan in congestive heart failure patients with and without hypoalbuminemia: a pilot study. Cardiovasc Ther 33:275–281CrossRefPubMed

12.

Shimizu K, Doi K, Imamura T, Noiri E, Yahagi N, Nangaku M, Kinugawa K (2015) Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure. Nephrology (Carlton) 20:405–412CrossRef

13.

Okayama D, Suzuki T, Shiga T, Minami Y, Tsuruoka S, Hagiwara N (2015) Blood urea nitrogen/creatinine ratio and response to tolvaptan in patients with decompensated heart failure: a retrospective analysis. Am J Cardiovasc Drugs 15:289–293CrossRefPubMed

14.

Iwatani H, Kawabata H, Sakaguchi Y, Yamamoto R, Hamano T, Rakugi H, Isaka Y (2015) Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study. Nephron 130:8–12CrossRefPubMed

15.

Toda H, Nakamura K, Nakahama M, Wada T, Watanabe A, Hashimoto K, Terasaka R, Tokioka K, Nishii N, Miyoshi T, Kohno K, Kawai Y, Miyaji K, Koide Y, Tachibana M, Yoshioka R, Ito H, Investigators Tolvaptan Registry (2016) Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: IMPORTANCE of preserved kidney size. J Cardiol 67:177–183CrossRefPubMed

16.

JCS Joint Working Group (2013) Guidelines for treatment of acute heart failure (JCS 2011). Circ J 77:2157–2201CrossRef

17.

Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) (2012) The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 33:1750–1757CrossRef

18.

Nakano Y, Mizuno T, Niwa T, Mukai K, Wakabayashi H, Watanabe A, Ando H, Takashima H, Murotani K, Waseda K, Amano T (2018) Impact of continuous administration of tolvaptan on preventing medium-term worsening renal function and long-term adverse events in heart failure patients with chronic kidney disease. Int Heart J 59:105–111CrossRefPubMed

19.

Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Mitsuda T, Miura A, Imai R, Iwamiya S, Ozaki Y, Kato T, Miura T, Watarai M, Murohara T (2016) Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease. Heart Vessels 31:1643–1649CrossRefPubMed

20.

Hanatani A, Shibata A, Kitada R, Iwata S, Matsumura Y, Doi A, Sugioka K, Takagi M, Yoshiyama M (2017) Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction. Heart Vessels 32:287–294CrossRefPubMed

21.

Matsukawa R, Kubota T, Okabe M, Yamamoto Y (2016) Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure. Heart Vessels 31:1650–1658CrossRefPubMed

22.

Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, Izawa A, Ikeda U (2016) Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol 67:399–405CrossRefPubMed

23.

Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni AP, Cook T, Swedberg K, Burnett JC Jr, Grinfeld L, Udelson JE, Zannad F, Gheorghiade M, Trial Investigators EVEREST (2013) Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J 34:835–843CrossRefPubMed

24.

Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, Sekiguchi H, Yamaguchi J, Ogawa H, Hagiwara N (2016) Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 3:177–188CrossRefPubMedPubMedCentral

25.

Kinugawa K, Inomata T, Sato N, Yasuda M, Shimakawa T, Bando K, Fukuta Y (2017) Who needs longer tolvaptan treatment? Int Heart J 58:30–35CrossRefPubMed

26.

Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297:1319–1331CrossRefPubMed

27.

Shoaf SE, Bricmont P, Dandurand A (2017) Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults. Eur J Clin Pharmacol 73:1399–1408CrossRefPubMedPubMedCentral

Title: The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge
Publication date: 01-10-2018
Published in: Heart and Vessels / Issue 10/2018
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-018-1177-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2018

Influence of visual–functional mismatch on coronary flow profiles after percutaneous coronary intervention: a propensity score-matched analysis

Extracellular volume fraction assessed using cardiovascular magnetic resonance can predict improvement in left ventricular ejection fraction in patients with dilated cardiomyopathy

Impact of the triglyceride level on coronary plaque components in female patients with coronary artery disease treated with statins

Diastolic dysfunction predicts the risk of contrast-induced nephropathy and outcome post-emergency percutaneous coronary intervention in AMI patients with preserved ejection fraction

Comparison of midterm outcomes of transcatheter aortic valve implantation in patients with and without previous coronary artery bypass grafting

The relationship between timing of prasugrel pretreatment and in-stent thrombus immediately after percutaneous coronary intervention for acute coronary syndrome: an optical coherence tomography study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page